Radar · Immunology in San Francisco
Best Immunology Companies in San Francisco, United States
The 54 best Immunology companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Alumis.
By Riya SenguptaFinancials
54companies tracked
$3.5Bdisclosed funding
0unicorns
41have raised
Ranked: Best Immunology companies in San Francisco
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Alumis Developer of therapeutics for the treatment of auto-immune disease | $529M | 24 mo ago | 16 | Martin Babler CEO | 88 patents TYK2 kinase inhibitor compounds and formulations for inflammatory disease treatment. | — |
| 2 | Sonoma Biotherapeutics Developer of T-cell-based therapies for autoimmune and degenerative diseases | $335M | 59 mo ago | 74 74 → 66 (-11%) | Fred Ramsdell Co-Founder | 54 patents Engineered immune cell therapies using chimeric antigen receptors and cytokine receptor designs | 1 job opening |
| 3 | Portola Pharma Developer of therapeutics for cardiovascular and autoimmune diseases | $296M | 85 mo ago | 369 | — | — | — |
| 4 | Lycia Therapeutics Developer of protein degradation drugs for the treatment of cancer and auto-immune disease | $227M | 26 mo ago | 22 22 → 37 (+68%) | Carolyn Bertozzi Founder | — | — |
| 5 | Attralus Developer of drugs for the treatment of Amyloid diseases | $197M | 29 mo ago | 23 | Jonathan Wall Co-Founder | 50 patents Engineered Fc‑fusion and antibody‑peptide biologics for amyloid disease therapy | — |
| 6 | DICE Developer of small molecule therapeutics for multiple disorders | $192M | 58 mo ago | 90 | — | 36 patents Video surveillance analytics and network communication protocol technologies | — |
| 7 | Verge Genomics Developer of artificial intelligence powered platform for drug discovery and development | $134M | 55 mo ago | 46 46 → 27 (-41%) | Peyton Huang Non-Executive Director and Co-Founder | — | 1 launch · 1 partnership |
| 8 | Walking Fish Therapeutics Developer of cell-based therapeutic solutions for treating cancer & immunological disorders | $123M | 53 mo ago | 37 | Seenu Kothakota Co-Founder | — | — |
| 9 | Crescendo Bioscience CLIA Laboratory focused on autoimmune and inflammatory diseases | $122M | 162 mo ago | 128 | — | — | — |
| 10 | Ouro Medicines Developer of therapeutics for people living with chronic immune-mediated diseases | $120M | 18 mo ago | — | Jaideep Dudani CEO | — | — |
| 11 | Blade Therapeutics Antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. | $93M | 80 mo ago | 30 | — | — | — |
| 12 | Principia Biopharma Developer of small-molecule drugs targeting autoimmune diseases and cancer | $90M | 131 mo ago | 122 | — | 717 patents Small-molecule BTK and immunoproteasome inhibitors for autoimmune and thrombotic therapies | — |
| 13 | TRexBio Developer of therapeutics for immunology and cancer 45Funding top 20%Moat top 31%News top 46%Talent bottom 49% All 6 signals ▾Fundingtop 20% Moattop 31% Newstop 46% Talentbottom 49% Marketbottom 47% Globalbottom 36% Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $85M | 5 mo ago | 65 | Johnston Erwin CEO | — | — |
| 14 | Electra Therapeutics Developer of therapies for immunological diseases and cancer | $84M | 9 mo ago | 4 | Adam Rosenthal Co-Founder & CEO | — | 1 launch |
| 15 | Symic Biomedical Developer of compounds to protect against tissue degradation and promote healing during illness or injury | $84M | 86 mo ago | 2 | — | 18 patents Synthetic extracellular‑matrix‑binding peptidoglycan biomaterials for wound and tissue repair | — |
| 16 | Vera Therapeutics Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases | $80M | 65 mo ago | 46 | Marshall Fordyce Founder & CEO | — | — |
| 17 | Kezar Life Sciences Developer of drugs targeting protein homeostasis for autoimmune disorders | $78M | 107 mo ago | 56 | John Fowler Co-Founder and Board Director | 157 patents Synthesis and formulation of peptide epoxyketone immunoproteasome inhibitors for protein secretion blockade | — |
| 18 | Rigel Developer of drugs for hematologic disorders, cancer, and rare immune disease | $76M | 65 mo ago | 147 147 → 292 (+99%) | Raul Rodriguez President and CEO | 6 patents Patents concentrated in computing, sensing & instrumentation | 3 partnerships |
| 19 | IgGenix Developer of therapeutic solutions for treating food allergy | $75M | 41 mo ago | 12 | Stephen Quake Co-Founder | 36 patents Peptide-based diagnostics and therapeutics targeting allergic disease prediction and treatment | — |
| 20 | Second Genome Developer of microbiome-based personalized medicine for a wide range of human health disorders | $64M | 108 mo ago | 37 | — | 135 patents Therapeutic proteins/peptides targeting gut barrier and immune modulation for autism and cancer | — |
| 21 | Therini Bio Limited information available | $62M | 14 mo ago | 13 13 → 15 (+15%) | Daniel Burgess CEO | — | — |
| 22 | Federation Bio Developer of biotherapeutic products for immune and metabolic disease | $50M | 69 mo ago | 39 | Michael Fischbach Co-Founder | — | — |
| 23 | Tolerion Developer of therapeutics to treat autoimmune diseases | $43M | 77 mo ago | 12 | John Statham Founder | 17 patents Stabilized DNA therapeutics and immunomodulatory treatments for type 1 diabetes | — |
| 24 | Siolta Therapeutics Provider of microbiome therapeutics for treating multiple diseases | $42M | 28 mo ago | 14 | Nikole Kimes Founder & CEO | — | — |
| 25 | GigaGen Developer of T-cell and antibody-based therapeutics | $36M | 102 mo ago | 36 | — | 198 patents Engineering recombinant polyclonal therapeutic proteins and immune‑repertoire fusion constructs. | — |
| 26 | Pathway Therapeutics Develops isoform specific inhibitors for oncology and inflammation | $29M | 160 mo ago | — | Julie Cherrington ex-CEO | — | — |
| 27 | Getsetup Developer of peptide-based therapies and companion diagnostics for autoimmune and infectious diseases | $23M | 56 mo ago | 86 | Deval Delivala Co-Founder | — | — |
| 28 | IMIDomics Developer of medicines for the treatment of immune-mediated inflammatory diseases | $16M | 28 mo ago | 25 | Sara Marsal Co-Founder | — | — |
| 29 | Osprey Pharmaceuticals USA Inflammatory/immune disease medications | $15M | 206 mo ago | — | Jack M. Anthony ex-CEO | — | — |
| 30 | X-37 Developer of drugs for cancer, autoimmune diseases and anticoaguulation using AI technology | $14M | 80 mo ago | 3 | David Collier Co-Founder & CEO | — | — |
| 31 | ParcelBio Developer of programmable technology to deliver mRNA to diverse cell types in the body | $13M | 5 mo ago | — | Christopher Carlson Co-Founder | — | — |
| 32 | Shennon Biotechnologies Developer of immune cell therapies against solid tumors and autoimmune disease | $13M | 40 mo ago | 8 | Li Sun Founder/CEO | 10 patents Engineered immune cell therapies and high-throughput microfluidic cell interaction screening | 5 job openings · 1 internship |
| 33 | Linkage Biosciences Life sciences solutions provider, enabling scientific research, discovery, and diagnostics | $13M | 158 mo ago | 34 | — | — | — |
| 34 | Infinimmune Developer of antibody-based drugs to treat various diseases | $12M | 43 mo ago | 10 | Michael Gibbons Co-Founder | — | — |
| 35 | Granza Bio Developer of therapeutics for the treatment of cancer | $8M | 24 mo ago | — | Ashwin Nandakumar Co-Founder & CEO | — | 1 award |
| 36 | TippingPoint Biosciences Developer of therapeutics for treating diseases caused by dysfunctional genome chromatin packaging | $7M | 3 mo ago | — | Geeta Narlikar Co-Founder | — | 1 partnership |
| 37 | Apeximmune Therapeutics Developer of biologics for cancer and auto-immune disease | $6M | 15 mo ago | 3 | — | — | — |
| 38 | Alixia Provider of cancer drug discovery and development platform | $2M | 24 mo ago | 5 | Helen Chen Co-Founder & CEO | — | — |
| 39 | Adheron Therapeutics Biotech firm pioneering therapies for autoimmune, inflammatory, and fibrotic diseases | $2M | 131 mo ago | — | David Lee Co-Founder | — | — |
| 40 | Ditto Biosciences Developer of therapies targeting autoimmune diseases by leveraging parasite biology | $500K | 6 mo ago | — | Emily Weiss Co-Founder & CTO | — | — |
| 41 | Serenity Bioworks Developer of protein-based therapeutics to address various medical conditions | $310K | 71 mo ago | 3 | Cody Shirriff Co-Founder & CEO | — | — |
| 42 | Beeline Therapeutics Developer of cell therapeutics for immunological diseases | $250K | 87 mo ago | — | Dimitre Simeonov Co-Founder | — | — |
Top 12 Immunology companies in San Francisco
#1
Series B · San Francisco, California · founded 2019 · 65 employees$85Mraised▾
Series B · San Francisco, California · founded 2019 · 65 employees
Developer of therapeutics for immunology and cancer. The company is developing transformative therapies by using a technology that maps human tissue and manipulates Tregs and other immune cells in a tissue-specific and disease-specific fashion.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 20%Moat
top 31%News
top 46%Talent
bottom 49%Market
bottom 47%Global
bottom 36%Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Jan 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
News: 2 BI events in 12 mo (of 3 tracked, 3 types) · +100% YoY · Top themes: Announcements, Capital raise
Audience (LinkedIn): 13k LinkedIn followers — 7.0% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jan 2026Series B$50M
- Nov 2024Series B$84M
- Mar 2022Series A$26M
- Jun 2021Series A$59M
Founders & team
Investors
Polaris Partners, SV Health Investors, Lilly, Johnson & Johnson Innovation, Pfizer, Alexandria
#2
Series C · San Francisco, California · founded 2018 · 4 employees$84Mraised▾
Series C · San Francisco, California · founded 2018 · 4 employees
Developer of therapies for immunological diseases and cancer. The company focuses on the development of therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. The company's lead product ELA026, is a monoclonal antibody to treat secondary hemophagocytic lymphohistiocytosis (sHLH).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Series C$183M
- Dec 2023Series B—
- Feb 2022Series B$84M
Founders & team
Investors
Westlake Village Biopartners, Orbimed, Redmile Group, Cormorant Asset Management, Cowen, New Leaf Venture Partners
#3
Seed · San Francisco, California · founded 2022$7Mraised▾
Seed · San Francisco, California · founded 2022
Developer of therapeutics for treating diseases caused by dysfunctional genome chromatin packaging. The company's proprietary platform addresses major limitations and challenges seen in the healthcare space by recreating the biological context of cancer-driving chromatin states in a controlled, cell-free environment. It focuses on disrupting or restoring the unique protein-protein and protein-DNA networks that package cell genomes.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Research Associate
Activity: 1 partnerships (incl. Freeflow) announced in 12 mo
Funding rounds
- Apr 2026Seed$4.5M
- Seed$2.5M
Founders & team
Investors
SOSV, Primer Sazze Partners, freeflow, StoryHouse Ventures, The Sontag Foundation, BrightEdge
Tech stack
CdnjsCloudflareCore-JsGoogle Font ApiGoogle Hosted LibrariesGoogle Maps
#4
Seed · San Francisco, California · founded 2023$13.2Mraised▾
Seed · San Francisco, California · founded 2023
Developer of programmable technology to deliver mRNA to diverse cell types in the body. The company has proprietary nanoparticle technology, which is ‘STAmP’, stabilizes the mRNA and utilizes an interchangeable, lock-and-key-like targeting mechanism which enables fully customizable mRNA medicines for kidney disorders, chronic liver diseases, and immune system dysregulation.
Funding rounds
- Feb 2026Seed$13.2M
Founders & team
Investors
Breyer Capital, General Catalyst, Y Combinator, Metaplanet, ZAKA, Surgepoint Capital
#5
Series A · San Francisco, California · founded 2016 · 13 employees$62.4Mraised▾
Series A · San Francisco, California · founded 2016 · 13 employees
Limited information available
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- May 2025Series A$39M
- Jan 2025Grant (prize money)$3M
- Mar 2023Conventional Debt—
- Mar 2023Series A$36M
Founders & team
Investors
Dolby Family Ventures, Alzheimer's Drug Discovery, SV Health Investors, MRLV, Sanofi Ventures, Lilly
#6
Acquired · San Francisco, California · founded 2024$120Mraised▾
Acquired · San Francisco, California · founded 2024
Developer of therapeutics for people living with chronic immune-mediated diseases. It offers a lead therapeutic candidate OM336 targeting B cell biology for the treatment of multiple myeloma and immune-mediated diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Activity: 1 partnerships (incl. THREAD) announced in 12 mo
Funding rounds
- Jan 2025Series A$120M
Founders & team
Investors
TPG, New Enterprise Associates, Monograph, GSK, UPMC, Boyu Capital
#7
Public · San Francisco, California · founded 2003 · 16 employees$529Mraised▾
Public · San Francisco, California · founded 2003 · 16 employees
Developer of therapeutics for the treatment of auto-immune disease. The lead candidate SK-001 is a potentially best-in-class TYK2 inhibitor for psoriasis treatment. The TYK2 is a gene that encodes a member of the tyrosine kinase which is a key mediator of inflammation and autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 10k LinkedIn followers — 5.4% of this cohort's audience
Funding rounds
- Jul 2024Post IPO$40M
- Mar 2024Series C$259M
- 2023Series B—
- Jan 2022Series B$200M
Founders & team
Investors
AyurMaya, Foresite Capital, Samsara BioCapital, VenBio, Cormorant Asset Management, SR One
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#8
Series C · San Francisco, California · founded 2020 · 22 employees$226.7Mraised▾
Series C · San Francisco, California · founded 2020 · 22 employees
Developer of protein degradation drugs for the treatment of cancer and auto-immune disease
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 3.7% of this cohort's audience
Funding rounds
- Apr 2024Series C$106.6M
- Sep 2021Series B$70.1M
- Jun 2020Series A$50M
Founders & team
Investors
Versant Ventures, Venrock, Janus Henderson Investors, Marshall Wace, Franklin Templeton Investments, Redmile Group
#9
Series B · San Francisco, California · founded 2019 · 23 employees$197Mraised▾
Series B · San Francisco, California · founded 2019 · 23 employees
Developer of drugs for the treatment of Amyloid diseases. The lead product AT-01 uses a polybasic peptide radiotracer technology and helps in the diagnostic of amyloid diseases. Other products include AT-02 & AT-03 which are PAR-SAP components that mediate binding to all types of amyloid and the Fc stimulates the immune system to remove amyloid.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Feb 2024Series B$56M
- Sep 2021Series B$116M
- Sep 2020Series A$25M
- Dec 2019Conventional Debt$175K
Founders & team
Investors
VenBio, Logos, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Citadel
#10
Series A · San Francisco, California · founded 2017 · 3 employees$6Mraised▾
Series A · San Francisco, California · founded 2017 · 3 employees
Developer of biologics for cancer and auto-immune disease. The company has a technology platform that combines bioinformatics with biological assays to identify immune-modulating targets to treat cancer, autoimmune disease, and transplantation.
Funding rounds
- Apr 2025Series A$21.3M
- Jun 2023Grant (prize money)$399.6K
- Mar 2021Seed$6M
Investors
HHS, Pharmaessentia Corporation, Daiwa Corporate Investment, Taya Venture Capital, Hercules Bioventure Partners, Huahai Pharmaceutical
#11
Seed · San Francisco, California · founded 2025$500Kraised▾
Seed · San Francisco, California · founded 2025
Developer of therapies targeting autoimmune diseases by leveraging parasite biology. The company identifies proteins from viruses, ticks, and worms to treat autoimmune disorders. These proteins could potentially calm and redirect the immune system. The company's platform identifies proteins with therapeutic potential for autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Jan 2026Seed$500K
Founders & team
Investors
Y Combinator
#12
Series C · San Francisco, California · founded 2016 · 14 employees$42Mraised▾
Series C · San Francisco, California · founded 2016 · 14 employees
Provider of microbiome therapeutics for treating multiple diseases. The company is focusing on the development of targeted human microbiome therapeutics for the prevention and treatment of chronic inflammatory diseases, starting with allergic diseases. The company's flagship product is STMC-103H for treating atopic dermatitis, food allergy, and allergic asthma.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- Mar 2024Series C$12M
- Aug 2023Grant (prize money)$300K
- Feb 2022Grant (prize money)$2.9M
- Sep 2020Series B$30M
Founders & team
Investors
SymBiosis, Khosla Ventures, Seventure Partners, Global Brain, TimeVentures, HHS
Funding & investor landscape
$3.5Btotal disclosed funding
42companies funded
149disclosed rounds
0rounds last 90 days
Most active investors
Y Combinator5 rounds
Notable founders
Johnston Erwin
CEO · TRexBio
Adam Rosenthal
Co-Founder & CEO · Electra Therapeutics
Geeta Narlikar
Co-Founder · TippingPoint Biosciences
Laura Hsieh
Co-Founder & CEO · TippingPoint Biosciences
Christopher Carlson
Co-Founder · ParcelBio
David Weinberg
Co-Founder & CEO · ParcelBio
Daniel Burgess
CEO · Therini Bio
Jaideep Dudani
CEO · Ouro Medicines
Martin Babler
CEO · Alumis
Carolyn Bertozzi
Founder · Lycia Therapeutics
Jonathan Wall
Co-Founder · Attralus
Emily Weiss
Co-Founder & CTO · Ditto Biosciences
Prism market signals · United States · country-scoped Prism corpus, 11,202,533 docs
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 55% → 62% across 2008–2026.
top research entities
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
leading researchers
Sarkar, Subhankar · F. Stephen Hodi · Jedd D. Wolchok · Michael A. Postow · Thomas Powles · Yan-Ruide Li · Abdullah Esmail · Julie R. Brahmer
▲
Breakthroughs3,482 · 25%
▲ 22%→25% share
▲1.1× share momentum0 median citations89% since 2021mostly methods-led
Tumor microenvironment research is surging — U.S. breakthrough papers grew 16-fold (30->481), signaling rapid mechanistic discovery.
rising sub-themes (early→recent)
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
Newly emergingBreast cancer 0→90 · Reprogramming 0→86 · Flow cytometry 0→44
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements6,585 · 47%
▼ 51%→47% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Transcriptome analysis newly emerged in advancements at 108 papers, reflecting broad clinical translation of multi-omic profiling.
rising sub-themes (early→recent)
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
Newly emergingTranscriptome 0→108 · Retrospective cohort study 0→62 · Phases of clinical research 0→59
Landmark Improved Survival with Ipilimumab in Patients with Metastatic Melanoma · 15,037 cites
▼
Concerns2,356 · 17%
▲ 16%→17% share
▲1.1× share momentum0 median citations87% since 2021mostly empirical
Clinical trial safety concerns are intensifying — relevant papers grew 19-fold (11->209) alongside newly flagged refractory-disease signals.
rising sub-themes (early→recent)
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Newly emergingMultiple myeloma 0→54 · MEDLINE 0→49 · Refractory (planetary science) 0→39
Landmark PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer · 30,895 cites
RESEARCH HOTSPOTS · United States
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1049 · +0.47
New York931 · +0.44
SF Bay Area496 · +0.50
Philadelphia473 · +0.46
Chicago379 · +0.45
Los Angeles309 · +0.48
Atlanta261 · +0.45
San Diego234 · +0.47
Seattle195 · +0.48
Pittsburgh179 · +0.43
PATENT SIGNAL · United States
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
10,389 filings4,528 assigneespeak 1314/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST222
Common questions
How many Immunology companies are there in San Francisco, United States?
Radar tracks 54 indexable Immunology companies headquartered in San Francisco, United States that meet our profile-completeness bar.
What is the total funding raised by Immunology companies in San Francisco, United States?
The Immunology companies in San Francisco, United States on this list have raised a combined $3.5B in disclosed equity funding across 42 funded companies.
Which is the highest-funded Immunology company in San Francisco, United States?
Alumis is the highest-funded Immunology company in San Francisco, United States, with $529M in disclosed equity funding.
How many Immunology companies in San Francisco, United States are funded?
42 of the 54 Immunology companies in San Francisco, United States on this list have disclosed at least one equity funding round.
How many Immunology unicorns are there in San Francisco, United States?
None of the Immunology companies in San Francisco, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in San Francisco, United States Immunology companies?
The most active investors in San Francisco, United States Immunology companies on this list include HHS, Alexandria, Janus Henderson Investors, JLABS, Lilly.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.